Innovations therapy: Mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors

Cancer and Metastasis Reviews

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Capdevila, Jaume ^a   Salazar, Ramón ^b   Halperín, Irene ^c   Abad, Albert ^d   Yao, James C ^e  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Duran i Reynals Hospital   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Everolimus; Gastroenteropancreatic neuroendocrine tumors; mTOR; Targeted therapy; Temsirolimus

Indexed keywords

BEVACIZUMAB; CYCLIN D1; EVEROLIMUS; HAMARTIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHIONINE; NEUROFIBROMIN; OCTREOTIDE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN S6; SOMATOSTATIN RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUBERIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANEMIA; ARTICLE; BRONCHUS CARCINOID; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOID; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE MUTATION; HUMAN; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NEUROFIBROMATOSIS; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMATITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VON HIPPEL LINDAU DISEASE;

CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; NEUROENDOCRINE TUMORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79953270375     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-011-9290-3     Document Type: Article

References (55)

1. DE Hansel A Rahman J Hermans, et al. 2003 Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression Modern Pathology 16 7 652 659 12861060 10.1097/01.MP.0000077416. 68489.50 (Pubitemid 36871497)
2. J Zhang Z Jia Q Li, et al. 2007 Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors Cancer 109 8 1478 1486 17340592 10.1002/cncr.22554 1:CAS:528: DC%2BD2sXlt1GmtL4%3D (Pubitemid 46595681)
3. M Furukawa M Raffeld C Mateo, et al. 2005 Increased expression of insulin-like growth factor I and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases Clinical Cancer Research 11 9 3233 3242 15867218 10.1158/1078-0432.CCR-04-1915 1:CAS:528:DC%2BD2MXjslOqsb0%3D (Pubitemid 40627870)
4. A Chaudhry V Papanicolaou K Oberg, et al. 1992 Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system Cancer Research 52 4 1006 1012 1310635 1:STN:280: DyaK387ksFKjsQ%3D%3D
5. O Nilsson B Wangberg L Kolby, et al. 1995 Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours International Journal of Cancer 60 5 645 651 10.1002/ijc.2910600514 1:STN:280:DyaK2M7msVSgsw%3D%3D
6. ML Fjällskog MH Lejonklou KE Oberg, et al. 2003 Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors Clinical Cancer Research 9 4 1469 1473 12684421 (Pubitemid 36418403)
7. U Wulbrand G Remmert P Zofel, et al. 2000 mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours European Journal of Clinical Investigation 30 8 729 739 10964166 10.1046/j.1365-2362.2000.00700.x 1:CAS:528:DC%2BD3cXmtlSlu7k%3D (Pubitemid 30604075)
8. GA Kaltsas GM Besser AB Grossman 2004 The diagnosis and medical management of advanced neuroendocrine tumors Endocrine Reviews 25 3 458 511 15180952 10.1210/er.2003-0014 1:CAS:528:DC%2BD2cXlvVeltLs%3D (Pubitemid 38780668)
9. D O'Toole A Couvelard V Rebours, et al. 2010 Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors Endocrine-Related Cancer 17 4 847 856 20570957 10.1677/ERC-09-0204
10. L Kolby G Persson S Franzen, et al. 2003 Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours The British Journal of Surgery 90 6 687 693 12808615 10.1002/bjs.4149 1:STN:280:DC%2BD3s3otVCrsg%3D%3D (Pubitemid 36760596)
11. CG Moertel J Rubin LK Kvols 1989 Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon Journal of Clinical Oncology 7 7 865 868 2738623 1:STN:280:DyaL1M3ptlWktQ%3D%3D (Pubitemid 19172459)
12. K Öberg I Norheim E Lind, et al. 1986 Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results Cancer Treatment Reports 70 11 1297 1304 2429764 (Pubitemid 17184294)
13. LY Dirix PB Vermeulen H Fierens, et al. 1996 Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors-an antiangiogenic effect? Anti-Cancer Drugs 7 2 175 181 8740722 10.1097/00001813-199603000-00005 1:CAS:528:DyaK28XjtF2ksbg%3D (Pubitemid 26151488)
14. A Rinke HH Muller C Schade-Brittinger, et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group Journal of Clinical Oncology 27 28 4656 4663 19704057 10.1200/JCO.2009.22.8510 1:CAS:528:DC%2BD1MXhtlGgtbnJ
15. CG Moertel M Lefkopoulo S Lipsitz, et al. 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma The New England Journal of Medicine 326 8 519 523 1310159 10.1056/NEJM199202203260804 1:STN:280:DyaK387itlejuw%3D%3D
16. MA Kouvaraki JA Ajani P Hoff, et al. 2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas Journal of Clinical Oncology 22 23 4762 4771 15570077 10.1200/JCO.2004.04.024 1:CAS:528:DC%2BD2MXhtFKq (Pubitemid 41185087)
17. W Sun S Lipsitz P Catalano, et al. 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 Journal of Clinical Oncology 23 22 4897 4904 16051944 10.1200/JCO.2005.03.616 1:CAS:528:DC%2BD2MXpsFWmt7c%3D (Pubitemid 46223995)
18. K Öberg S Jelic 2009 Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up Annals of Oncology 20 Suppl 4 150 153 19454440
19. K Öberg L Kvols M Caplin, et al. 2004 Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system Annals of Oncology 15 6 966 973 15151956 10.1093/annonc/mdh216 (Pubitemid 39004355)
20. J Capdevila R Salazar 2009 Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors Target Oncology 4 4 287 296 10.1007/s11523-009-0128-7
21. S Wullschleger R Loewith MN Hall 2006 TOR signaling in growth and metabolism Cell 124 3 471 484 16469695 10.1016/j.cell.2006.01.016 1:CAS:528:DC%2BD28Xhslaqs74%3D (Pubitemid 43199434)
22. F Meric-Bernstam AM Gonzalez-Angulo 2009 Targeting the mTOR signaling network for cancer therapy Journal of Clinical Oncology 27 13 2278 2287 19332717 10.1200/JCO.2008.20.0766 1:CAS:528:DC%2BD1MXlvFOgs7k%3D
23. A Arcaro AS Guerreiro 2007 The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications Current Genomics 8 5 271 306 19384426 10.2174/138920207782446160 1:CAS:528:DC%2BD1cXhsVGmsQ%3D%3D (Pubitemid 351210980)
24. R Yuan A Kay WJ Berg, et al. 2009 Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Journal of Hematology and Oncology 2 45 19860903 10.1186/1756-8722-2-45
25. S Vignot S Faivre D Aguirre, et al. 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Annals of Oncology 16 4 525 537 15728109 10.1093/annonc/mdi113 1:STN:280:DC%2BD2M7kvVWmsQ%3D%3D (Pubitemid 40613318)
26. TF Franke CP Hornik L Segev, et al. 2003 PI3K/Akt and apoptosis: size matters Oncogene 22 56 8983 8998 14663477 10.1038/sj.onc.1207115 1:CAS:528:DC%2BD3sXpsFOmsrg%3D (Pubitemid 38121699)
27. J Paez WR Sellers 2003 PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling Cancer Treatment and Research 115 145 167 12613196 10.1007/0-306-48158-8-6 1:CAS:528:DC%2BD3sXnt12gs7k%3D
28. J LoPiccolo GM Blumenthal WB Bernstein, et al. 2008 Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations Drug Resistance Updates 11 1-2 32 50 18166498 10.1016/j.drup.2007.11.003 1:CAS:528:DC%2BD1cXlslWqurw%3D
29. G von Wichert PM Jehle A Hoeflich, et al. 2000 Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells Cancer Research 60 16 4573 4581 (Pubitemid 32103642)
30. JJ Van Gompel H Chen 2004 Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells Surgery 136 6 1297 1302 15657590 10.1016/j.surg.2004.06.061 (Pubitemid 39647548)
31. MC Zatelli M Minoia C Martini, et al. 2010 Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids Endocrine-Related Cancer 17 3 719 729 20554786 10.1677/ERC-10-0097 1:CAS:528:DC%2BC3cXht1KqsLnM
32. AR Tee DC Fingar BD Manning, et al. 2002 Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling Proceedings of the National Academy of Sciences of the United States of America 99 21 13571 13576 12271141 10.1073/pnas.202476899 1:CAS:528:DC%2BD38XotVKmsLY%3D (Pubitemid 35215423)
33. S Verhoef R van Diemen-Steenvoorde WL Akkersdijk, et al. 1999 Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood European Journal of Pediatrics 158 4 284 287 10206124 10.1007/s004310051073 1:STN:280:DyaK1M3itV2ltw%3D%3D (Pubitemid 29183702)
34. MS Eledrisi CA Stuart M Alshanti 2002 Insulinoma in a patient with tuberous sclerosis: Is there an association? Endocrine Practice 8 2 109 112 11942775 (Pubitemid 34248088)
35. D Dworakowska AB Grossman 2009 Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review Endocrine-Related Cancer 16 1 45 58 18978035 10.1677/ERC-08-0142 1:CAS:528:DC%2BD1MXptlOiu7g%3D
36. S Hattori M Maekawa S Nakamura 1992 Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21 Oncogene 7 3 481 485 1549362 1:CAS:528:DyaK38XisFaqs74%3D
37. CM Johannessen EE Reczek MF James, et al. 2005 The NF1 tumor suppressor critically regulates TSC2 and mTOR Proceedings of the National Academy of Sciences of the United States of America 102 24 8573 8578 15937108 10.1073/pnas.0503224102 1:CAS:528:DC%2BD2MXlsFCgtrs%3D (Pubitemid 40862777)
38. JA Blansfield L Choyke SY Morita, et al. 2007 Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs) Surgery 142 6 814 818 18063061 10.1016/j.surg.2007.09.012 discussion 818 e1-2 (Pubitemid 350184104)
39. JA Forsythe BH Jiang NV Iyer, et al. 1996 Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 Molecular and Cellular Biology 16 9 4604 4613 8756616 1:CAS:528: DyaK28XltFKjsrc%3D (Pubitemid 26272112)
40. ER Woodward ER Maher 2006 Von Hippel-Lindau disease and endocrine tumour susceptibility Endocrine-Related Cancer 13 2 415 425 16728571 10.1677/erc.1.00683 1:CAS:528:DC%2BD28XntF2mtLg%3D (Pubitemid 43886666)
41. RV Thakker 2010 Multiple endocrine neoplasia type 1 (MEN1) Best Practice & Research. Clinical Endocrinology & Metabolism 24 3 355 370 10.1016/j.beem.2010.07.003 1:CAS:528:DC%2BC3cXhtFCls7rM
42. LV Debelenko Z Zhuang MR Emmert-Buck, et al. 1997 Allelic deletions on chromosome 11q13 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors Cancer Research 57 11 2238 2243 9187127 1:CAS:528:DyaK2sXjslKjsb4%3D (Pubitemid 27247044)
43. O Jakobovitz D Nass L DeMarco, et al. 1996 Carcinoid tumors frequently display genetic abnormalities involving chromosome 11 The Journal of Clinical Endocrinology and Metabolism 81 9 3164 3167 8784062 10.1210/jc.81.9.3164 1:CAS:528:DyaK28Xls1OrsLs%3D (Pubitemid 26296181)
44. K Öberg 2009 Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors) Current Opinion in Endocrinology, Diabetes and Obesity 16 1 72 78 10.1097/MED.0b013e328320d845
45. EH Wang SA Ebrahimi AY Wu, et al. 1998 Mutation of the MENIN gene in sporadic pancreatic endocrine tumors Cancer Research 58 19 4417 4420 9766672 1:CAS:528:DyaK1cXmsVyqtr0%3D (Pubitemid 28450045)
46. E Missiaglia I Dalai S Barbi, et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway Journal of Clinical Oncology 28 2 245 255 19917848 10.1200/JCO.2008.21.5988 1:CAS:528: DC%2BC3cXjtVSqt7c%3D
47. Temsirolimus (Torisel®) (2010). Full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022088s008lbl.pdf. Accessed 13 Oct 2010.
48. I Durán J Kortmansky D Singh, et al. 2006 A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas British Journal of Cancer 95 9 1148 1154 17031397 10.1038/sj.bjc.6603419 (Pubitemid 44660065)
49. Everolimus (Afinitor®) (2010). Full prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022334s004lbl.pdf. Accessed 13 Oct 2010.
50. K Zitzmann EN De Toni S Brand, et al. 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells Neuroendocrinology 85 1 54 60 17310129 10.1159/000100057 1:CAS:528:DC%2BD2sXjslOks7w%3D (Pubitemid 46550026)
51. J Tabernero F Rojo E Calvo, et al. 2008 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors Journal of Clinical Oncology 26 10 1603 1610 18332469 10.1200/JCO.2007.14.5482 1:CAS:528:DC%2BD1cXltlWiu7c%3D
52. JC Yao AT Phan DZ Chang, et al. 2008 Efficacy of RAD001 (Everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study Journal of Clinical Oncology 26 26 4311 4318 18779618 10.1200/JCO.2008.16.7858
53. JC Yao C Lombard-Bohas E Baudin, et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial Journal of Clinical Oncology 28 1 69 76 19933912 10.1200/JCO.2009.24.2669 1:CAS:528:DC%2BC3cXhtF2rsr4%3D
54. Pavel, M.; Hainsworth, J.D.; Baudin, E.; et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus plus octreotide LAR vs ersus placebo plus octreotide LAR in patients with advanced neuroendocrine tumors (NET) (RADIANT-2). In: 35th European Medical Oncology Society; 2010; Milan, Italy.
55. Yao, J.C.; Shah, M.H.; Ito, T.; et al. (2010). A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). In: 35th European Society Medical Oncology; 2010; Milan, Italy